MBD2 Knockout T-47D-CAS9 Cell Line

The choice depends on whether you are studying MBD2 (methyl-CpG binding domain protein 2)'s role as a methylated DNA reader within the NuRD chromatin remodeling complex or its emerging functions in tumor suppression. The Knockout line is the standard tool for asking whether MBD2 is required for these processes — MBD2 binds methylated CpG islands through its conserved MBD domain and recruits the NuRD complex (containing HDAC1/2, CHD3/4, MTA1/2/3, RBBP4/7) to repress methylated gene promoters. Overexpression is useful for studying MBD2 in heterologous expression contexts. For breast cancer epigenetics research, the EDITGENE MBD2 Knockout in T-47D-CAS9 is highly relevant — T-47D is a luminal A breast cancer cell line (ER+, PR+, HER2-), and MBD2-NuRD-mediated repression of tumor suppressor genes contributes to luminal breast cancer biology. Rescue with wild-type or MBD-domain-mutant (methylated DNA-binding deficient) MBD2 enables structure-function studies. The knockout is valuable for studying MBD2-targeted approaches in cancer and emerging anti-NuRD therapeutic strategies. The constitutive Cas9 expression in T-47D-CAS9 enables further combinatorial gene editing studies.

Primary applications: • Methylated DNA binding: ChIP-seq for MBD2 occupancy at methylated CpG islands to characterize MBD2-dependent genome localization. • NuRD complex assembly: co-immunoprecipitation analysis of MBD2 with NuRD components (HDAC1/2, CHD3/4, MTA1/2/3) in the absence of MBD2. • Methylated gene de-repression: RNA-seq analysis at hypermethylated tumor suppressor genes to characterize MBD2-dependent silencing. • Combinatorial editing: the T-47D-CAS9 background enables additional gene editing experiments within the MBD2-null context. EDITGENE recommends this model for researchers investigating MBD2-mediated epigenetic silencing, NuRD-dependent transcriptional repression, and hormone receptor-positive breast cancer epigenetics.

Yes. MBD2 rescue experiments require attention to NuRD complex integration: • Construct design: use a codon-modified MBD2 sequence with a small C-terminal tag (FLAG, HA). MBD2 has N-terminal MBD (methyl-CpG binding) domain and C-terminal coiled-coil for NuRD complex recruitment — preserve all elements. • MBD-domain-mutant rescue: methylated DNA-binding residue mutations (e.g., R26A, Y34A in the MBD pocket) abolish methylated DNA binding and serve as the standard specificity control. • NuRD-binding-deficient rescue: coiled-coil mutations disrupt NuRD recruitment. • Functional readout: rescue should restore methylated gene silencing and NuRD complex recruitment to target promoters. T-47D-CAS9-specific considerations: • T-47D-CAS9 is a luminal A breast cancer cell line (ER+, PR+, HER2-) constitutively expressing Cas9 for additional editing — the Cas9 expression must be considered when designing further knockout or rescue experiments. • Hormone receptor positivity makes T-47D-CAS9 a relevant model for hormone-dependent breast cancer biology. • Lentiviral transduction is supported; the Cas9 expression cassette location should be characterized before designing complex multi-locus modifications.